Symbols

Symbols

EVGN

EVGN

Evogene's CEO to present at H.C. Wainwright Global Investment Conference 2025.

Sunday Aug 24, 2025

Evogene Completes Sale of Lavie Bio to ICL Group, Enhancing Global Reach in Sustainable Agriculture

Wednesday Aug 20, 2025

Evogene Reports Q2 2025 Financial Results: Revenue Up 39%, Operating Expenses Down 31%

Evogene's Q2 Earnings Show Revenue Growth Amidst Losses

Evogene Reports Q2 Revenue of $884,000, Up from $605,000 Last Year, and EPS of 50c, a Significant Improvement from Last Year's (85c) Loss.

Evogene's Q2 Earnings Show Revenue Growth Amidst Losses

Tuesday Aug 19, 2025

Evogene Beats Q2 EPS Estimates, Misses Revenue Target by $0.05M

Monday Aug 18, 2025

Evogene Q2 2025 Earnings Preview: EPS and Revenue Estimates Ahead of August 19th Release

Tuesday Aug 12, 2025

Evogene and Tel Aviv University collaborate on drug discovery for metabolite-related diseases.

Wednesday Aug 06, 2025

ICL Group Declares $0.04260 Cash Dividend, Payable September 17, 2025

Tuesday Jul 29, 2025

Evogene Announces Q2 2025 Financial Results Release, Schedules Zoom Conference Call for August 19, 2025.

Wednesday Jul 09, 2025

Evogene shares fall 1.42% premarket after selling ag-biologicals subsidiary Lavie Bio to ICL Group.

Tuesday Jul 08, 2025

Evogene completes sale of ag-biologicals unit to ICL Group.

Thursday Jun 26, 2025

Evogene Ltd. shares rise 1.47% premarket after ICL Group Ltd. signs potash supply agreements with China and India.

Wednesday Jun 18, 2025

Evogene Announces Annual General Meeting for August 2025, Directors Up for Re-Election

Thursday Jun 12, 2025

Evogene Unveils Advanced AI Model for Small Molecule Discovery, Expands ChemPass AI Capabilities

Lake Street Keeps Buy Rating on Evogene with $3.50 PT, Analyst Consensus at Moderate Buy with 209.73% Upside

Evogene Completes First-In-Class Foundation Model for Generative Molecule Design with Google Cloud.

Wednesday Jun 11, 2025

Evogene Ltd. shares fall 10.62% in premarket due to market conditions.

Evogene Ltd. shares fall 4.42% in premarket due to market conditions.